Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma.

Trial Profile

Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Apr 2016

At a glance

  • Drugs Octreotide (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 09 Sep 2011 Actual end date added as 1 Mar 2008 as reported by ClinicalTrials.gov.
    • 01 Jul 2009 Results published in the European Journal of Cancer.
    • 27 Jun 2009 Results were reported at the 11th World Congress on Gastrointestinal Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top